ClinicalTrials.gg
CompletedNCT01022437Updated Dec 18, 2015

Geranium Oil and Its Components for the Relief of Numbness-OB 100

An interventional study of Geranium Oil with component PN-34 in Nerve Conduction and Numbness, sponsored by Pennington Biomedical Research Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-18.

Sponsored by Pennington Biomedical Research Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the effectiveness of geranium oil and its components in the relief of numbness and the restoration of sensations.

Read the detailed description

This is a pilot study to define the time course, the incidence of sensation restoration and the improvement in nerve conduction in people with numbness by using topical geranium oil.

02

Conditions studied

  • Nerve Conduction
  • Numbness

Browse trials for

03

In context

Hypesthesia

47 studies on the registry are indexed under Hypesthesia; 12 are open to participants now.

This study's enrollment of 13 is below the median of 50 across 43 interventional studies indexed under Hypesthesia.

Browse Hypesthesia studies →

Lead sponsor

Pennington Biomedical Research Center is the lead sponsor of 284 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Neuropathy with the inability to feel touch in a standard nylon filament test
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing
  • Known allergies to geranium oil or geranium oil fractions
  • Open sore in the area of numbness
  • Migraine headaches or headaches to strong smells
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Geranium Oil and component PN-34

    Other: Geranium Oil with component PN-34

Interventions

  • OtherGeranium Oil with component PN-34

    Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.

06

What researchers measure

Primary outcomes

  1. Response to numbness relief and restoration of sensation

    Time frame: 12 weeks

07

Study locations

1 site
  • Penningto Biomedical Research Center
    Baton Rouge, Louisiana 70809, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01022437
Responsible party
Frank Greenway (Clinical Medical Doctor, Pennington Biomedical Research Center) — Principal investigator
First posted
Dec 1, 2009
Start date
Dec 2008
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Dec 18, 2015

Study contacts

Alok Gupta, MD
principal investigator · Pennington Biomedical Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion